CAF23 |
|
Vaxjo ID |
393 |
|
Vaccine Adjuvant Name |
CAF23 |
|
Alternative Names |
it is referred to as a combination adjuvant formulation containing CAF01 and DSPC-RA. |
|
Adjuvant VO ID |
VO_0005675
|
|
Description |
CAF23 is a liposome-based adjuvant formulation that combines two delivery systems: CAF01, which forms a depot at the injection site, and a fast-draining formulation containing retinoic acid (DSPC-RA) to condition lymph nodes for a mucosal immune response. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Structure |
The structure of CAF23 consists of liposomes containing retinoic acid and other components from the CAF01 formulation |
|
Storage |
CAF23 should be stored at 2−8 °C until use |
|
Preparation |
CAF23 is prepared by combining the two liposomal formulations (CAF01 and DSPC-RA) and ensuring proper stability and size through centrifugation and formulation techniques. |
|
Function |
We show that CAF23, administered by the subcutaneous route induces an antigen specific intestinal IgA response, making it a promising candidate adjuvant for vaccines against enteric diseases. |
|
Safety |
CAF23 has shown a favorable safety profile in preclinical studies, but specific safety data in clinical trials are not provided. |
| References |
Christensen et al., 2019: Christensen D, Bøllehuus Hansen L, Leboux R, Jiskoot W, Christensen JP, Andersen P, Dietrich J. A Liposome-Based Adjuvant Containing Two Delivery Systems with the Ability to Induce Mucosal Immunoglobulin A Following a Parenteral Immunization. ACS nano. 2019; 13(2); 1116-1126. [PubMed: 30609354].
|
